124 related articles for article (PubMed ID: 6262142)
21. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
22. A note on single- and two-dose immunogenicity tests of inactive virus vaccine in chicks.
Slonim D; Drevo M
J Hyg Epidemiol Microbiol Immunol; 1976; 21(3):368-70. PubMed ID: 1033226
[TBL] [Abstract][Full Text] [Related]
23. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
24. Stabilizing effect of magnesium chloride and sucrose on Sabin live polio vaccine.
Mirchamsy H; Shafyi A; Mahinpour M; Nazari P
Dev Biol Stand; 1978; 41():255-7. PubMed ID: 223912
[TBL] [Abstract][Full Text] [Related]
25. Swedish inactivated polio vaccine: laboratory standardization and clinical experience over a 30-year period.
Böttiger M; Larsson B
Biologicals; 1992 Dec; 20(4):267-75. PubMed ID: 1305403
[TBL] [Abstract][Full Text] [Related]
26. Direct enzyme linked immunosorbent assay (ELISA) for quantification of poliomyelitis virus D-antigen.
Souvras M; Montagnon B; Fanget B; van Wezel AL; Hazendonk AG
Dev Biol Stand; 1980; 46():197-202. PubMed ID: 6244997
[TBL] [Abstract][Full Text] [Related]
27. Manipulation of the cellular binding properties of poliovirus: implications for non-target effects of recombinant vaccines.
Whelan SP; Evans D; Almond JW
Dev Biol Stand; 1995; 84():129-36. PubMed ID: 7796945
[No Abstract] [Full Text] [Related]
28. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
29. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis.
Salk J; van Wezel AL; Stoeckel P; van Steenis G; Schlumberger M; Meyran M; Rey JL; Lapinleimu K; Böttiger M; Cohen H
Dev Biol Stand; 1981; 47():181-98. PubMed ID: 7194827
[TBL] [Abstract][Full Text] [Related]
30. [Effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine and its safety].
Bian CX; Jiang SD; Yang JY; Sun MB; Xie MX; Zhang XW; Liao GY; Li WD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):44-6. PubMed ID: 17429533
[TBL] [Abstract][Full Text] [Related]
31. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen.
Salk J; Stoeckel P; van Wezel AL; Lapinleimu K; van Steenis G
Ann Clin Res; 1982 Dec; 14(5-6):204-12. PubMed ID: 7171229
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats.
Kersten GF; Lantinga M; Hazendonk T; Beuvery EC
Biologicals; 1995 Jun; 23(2):179-83. PubMed ID: 7546661
[TBL] [Abstract][Full Text] [Related]
33. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.
Minor PD; Dunn G; Ramsay ME; Brown D
J Med Virol; 2005 Jan; 75(1):153-60. PubMed ID: 15543587
[TBL] [Abstract][Full Text] [Related]
34. [Antibody production against poliovirus N and H antigens by immunization of guinea pigs].
Mietens C; Fuhrmeister U
Arch Gesamte Virusforsch; 1971; 34(1):23-31. PubMed ID: 4329437
[No Abstract] [Full Text] [Related]
35. Vaccines based on recombinant antigen strategies.
Minor P
Dev Biol (Basel); 2001; 105():189-94. PubMed ID: 11763327
[No Abstract] [Full Text] [Related]
36. Validation of the toxin-binding inhibition (ToBI) test for the estimation of the potency of the tetanus toxoïd component in vaccines.
van der Gun J; Akkermans A; Hendriksen C; van de Donk H
Dev Biol Stand; 1996; 86():199-206. PubMed ID: 8785949
[TBL] [Abstract][Full Text] [Related]
37. [The immune response by application of isolated procapsids of poliovirus type 1 and coxsackievirus type B4 (author's transl)].
Schmidt WA; Klein M
Zentralbl Bakteriol Orig A; 1973 Jul; 224(2):178-83. PubMed ID: 4147732
[No Abstract] [Full Text] [Related]
38. Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd.
Von Seefried A; Chun JH; Grant JA; Letvenuk L; Pearson EW
Rev Infect Dis; 1984; 6 Suppl 2(Suppl 2):S345-9. PubMed ID: 6330837
[TBL] [Abstract][Full Text] [Related]
39. [Test of the potency of trivalent oral polio vaccines: comparison of 2 methods of reading].
Chocarro LB; Manau MV
Rev Argent Microbiol; 1987; 19(2):65-9. PubMed ID: 2459727
[TBL] [Abstract][Full Text] [Related]
40. Regulation and standardization of IPV and IPV combination vaccines.
Baca-Estrada M; Griffiths E
Biologicals; 2006 Jun; 34(2):159-61. PubMed ID: 16682221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
